Exelixis, Inc. (EXEL)

22.52 +0.03 (+0.13%) At close: 04:00PM EDT

Exelixis, Inc.

1851 Harbor Bay Parkway
Alameda, CA 94502
United States
650 837 7000
https://www.exelixis.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,310

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Stelios Papadopoulos Ph.D.	Co-Founder & Chair of the Board	109k	N/A	1948
Dr. Michael M. Morrissey Ph.D.	CEO, President & Director	2.31M	N/A	1961
Mr. Christopher J. Senner	Executive VP & CFO	1.09M	2.93M	1968
Mr. Jeffrey J. Hessekiel J.D.	Executive VP, General Counsel & Secretary	959.68k	N/A	1969
Mr. Patrick J. Haley M.B.A.	Executive Vice President of Commercial	844.64k	1.76M	1976
Ms. Susan T. Hubbard	Executive Vice President of Public Affairs & Investor Relations	N/A	N/A	N/A
Ms. Laura Dillard	Executive Vice President of Human Resources	N/A	N/A	N/A
Dr. Peter Lamb Ph.D.	Executive VP of Scientific Strategy	909.46k	10.72M	1961
Dr. Anne Champsaur M.D.	Senior Vice President of Drug Safety	N/A	N/A	N/A
Dr. William Berg M.D.	Senior Vice President of Medical Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Corporate governance

Exelixis, Inc.’s ISS governance QualityScore as of 1 April 2024 is 3. The pillar scores are Audit: 5; Board: 2; Shareholder rights: 4; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.